18:25 , Nov 30, 2018 |  BC Week In Review  |  Clinical News

FDA approves two drugs for first-line AML

FDA approved on Nov. 28 two drugs for first-line treatment of acute myelogenous leukemia, setting off a race in a setting that's been void of new approvals for patients who do not harbor an FMS-like...
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
20:05 , Nov 26, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling A Bayesian network-based method of analyzing non-silent mutations could help identify mutational interactions across different cancer types to predict patient outcomes and identify targets or new indications for drugs. The method involves...
20:40 , Nov 21, 2018 |  BC Extra  |  Company News

FDA approves two drugs for first-line AML

FDA approved on Wednesday two drugs for first-line treatment of acute myelogenous leukemia, setting off a race in a setting that's been void of new approvals for patients who do not harbor an FMS-like tyrosine...
01:14 , Oct 6, 2018 |  BioCentury  |  Finance

Large cap comeback

The biotech sector continued to be a stock pickers’ market through 3Q18 as there was a near even split between global biotech stocks that gained and lost value in the quarter. While 1H18 saw investors...
00:48 , Oct 6, 2018 |  BioCentury  |  Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
15:18 , Sep 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Cell culture and mouse studies suggest inhibiting GLS could enhance the efficacy of radiation or reactive oxygen species (ROS)-inducing drugs in IDH1-mutant glioma. In a human glioma cell line expressing mutant IDH1,...
20:04 , Aug 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Alt-neoantigens

Neoantigens derived from alternative splicing could broaden the target space for cancer vaccines and T cell therapies, according to two studies published this month. While questions remain about whether they are sufficiently immunogenic to create...
15:28 , Jul 27, 2018 |  BC Week In Review  |  Clinical News

FDA approves Agios' IDH1 inhibitor Tibsovo for AML

FDA approved Tibsovo ivosidenib (formerly AG-120) from Agios Pharmaceuticals Inc. (NASDAQ:AGIO) to treat relapsed or refractory acute myelogenous leukemia (AML) in adults with a susceptible isocitrate dehydrogenase 1 (IDH1) mutation. Tibsovo is the first FDA-approved...
16:44 , Jul 20, 2018 |  BC Extra  |  Company News

FDA approves Agios' IDH1 inhibitor for AML

FDA approved Tibsovo ivosidenib (formerly AG-120) from Agios Pharmaceuticals Inc. (NASDAQ:AGIO) on Friday to treat relapsed or refractory acute myelogenous leukemia in adults with a susceptible isocitrate dehydrogenase 1 (IDH1) mutation. Tibsovo is the first...